FDA approval of Akynzeo®

The U.S. Food & Drug Administration approves Helsinn's drug 'Akynzeo' for the prevention of acute and delayed phase nausea and vomiting in patients undergoing cancer chemotherapy.

CHMP Positive Opinion for Akynzeo® in the European Union

European Medicines Agency (EMA) has adopted a positive opinion recommending that Akynzeo®(netupitant-palonosetron),  be granted approval for the prevention of acute and delayed nausea and vomiting in patients undergoing highly emetogenic cisplatin‑based and moderately emetogenic cancer chemotherapy.


Prev Next

May 27, 2015

The European approval of ALOXI® for paediatric use follows the FDA approval in May 2014 of AL...


May 20, 2015

Helsinn, a Swiss Group focused on building quality cancer care, announced today that three ab...


May 08, 2015

TGA Approves AKYNZEO® (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Na...


April 15, 2015

Decision of the National Comprehensive Cancer Network (NCCN) to include AKYNZEO® in the 2015 ...